

1 **Title:**

2 Mpox vaccination uptake in a UK community sample of gay, bisexual, and other men who have sex
3 with men (GBMSM) the year following the 2022 Clade IIb mpox outbreak

4 **Authors:**

5 Dolores Mullen¹ (dolores.mullen@ukhsa.gov.uk, [ORCID ID: 0009-0006-1741-1449](#)),

6 Jessica Edney¹ (jessica.edney@ukhsa.gov.uk, [ORCID ID: 0009-0003-9920-1848](#)),

7 Dawn Phillips¹ (dawn.phillips@ukhsa.gov.uk, [ORCID ID: 0009-0001-1508-1697](#)),

8 Ruth Wilkie¹ (ruth.wilkie@wales.nhs.uk, [ORCID ID: 0009-0000-9568-1862](#)),

9 David Reid² (david.reid@ucl.ac.uk, [ORCID ID: 0000-0001-6832-2418](#)),

10 Catherine M Lowndes¹ (kathy.lowndes@ukhsa.gov.uk, [ORCID ID: 0009-0000-9171-9149](#)),

11 Erna Buitendam¹ (erna.buitendam@ukhsa.gov.uk, [ORCID ID: 0000-0002-4612-7408](#)),

12 Katy Sinka¹ (katy.sinka@ukhsa.gov.uk, ORCID ID: 0000-0001-8596-0649),

13 Sema Mandal¹ (sema.mandal@ukhsa.gov.uk, ORCID ID: 0000-0003-3379-3118),

14 Catherine H Mercer² (c.mercer@ucl.ac.uk, [ORCID ID: 0000-0002-4220-5034](#)),

15 John Saunders^{1,2} (john.saunders@uksa.gov.uk, [ORCID ID: 0000-0003-3020-9916](#)),

16 Hamish Mohammed^{1,2} (hamish.mohammed@ukhsa.gov.uk, [ORCID ID: 0000-0002-2060-7286](#)),

17 Dana Ogaz¹ (dana.ogaz@ukhsa.gov.uk, [ORCID ID: 0000-0002-1900-8892](#))

18 **Affiliations:**

19 ¹ Blood Safety, Hepatitis, STIs and HIV Division, National Infection Service, UK Health Security Agency,
20 Colindale, UK

21 ² Institute for Global Health, University College London, London, United Kingdom

22 **Corresponding Author:**

23 Dolores Mullen, 61 Colindale Avenue, UK Health Security Agency, London, UK NW9 5EQ,
24 dolores.mullen@ukhsa.gov.uk

25 **Ethics statement:**

26 Ethical approval of this study was provided by the UKHSA Research and Ethics Governance Group
27 (REGG; ref: R&D 524). Online informed consent was received from all participants and all methods
28 were performed in accordance with guidelines and regulations set by the UKHSA REGG.

29 **Funding:**

30 This study did not receive any funding.

31 **Competing interests:**

32 Authors have no competing interests to declare.

33 **Data availability statement:** NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 The data that support the findings of this study are available upon reasonable request from the UK
35 Health Security Agency (UKHSA). Requests can be directed to riish_survey@ukhsa.gov.uk.

36 **Contributors:**

37 DM, DP, RW, DR, EB, CML, SM, CHM, JS, HM, DO reviewed and updated the survey instrument.
38 Survey implementation, data collection and data management were carried out by DM, JE, DP, RW,
39 HM, DO. DM, HM, DO conceived secondary analysis design with review and contributions from CHM,
40 JS, KS, SM. DM conducted analyses and, with DO, wrote the first manuscript draft. All authors
41 contributed to successive drafts and reviewed and approved the final manuscript.

42 **Acknowledgements**

43 The authors thank all the participants involved in this study.

44

45 **Abstract (word count: 183)**

46 Mpxv is an infectious disease transmitted through close contact. It is caused by the monkeypox virus,
47 which is endemic to some countries of West and Central Africa. A multi-country outbreak of mpox
48 occurred in 2022, and the UK experienced rapid community transmission associated with sexual
49 contact, mainly, but not exclusively among networks of gay, bisexual, and other men who have sex
50 with men (GBMSM). In response to the outbreak in the UK, a reactive mpox vaccination programme
51 was targeted to those most at risk. We explore the uptake and course completion of mpox
52 vaccination in GBMSM taking part in an online survey in 2023. Findings from this community sample
53 indicate vaccination uptake in around two-thirds of participants meeting mpox proxy eligibility
54 criteria with high levels of course completion among all and eligible participants that were ever
55 vaccinated. Vaccine non-offer was a barrier to uptake, as nearly a third of those eligible but
56 unvaccinated reported never having received an mpox vaccine offer. Continued targeting of
57 vaccination to GBMSM at highest risk of mpox at SHS, with community-support, will help facilitate
58 equitable uptake of vaccination.

59

60 **Scientific Letter (word count: 734)**

61 Control of the 2022 Clade IIb mpox outbreak in the UK, primarily affecting gay, bisexual, and other
62 men who have sex with men (GBMSM), was achieved through behavioural change and targeted
63 vaccination, both supported by coproduced health promotion (1, 2). In November 2022, the Joint
64 Committee on Vaccination and Immunisation recommended a routine mpox vaccination programme
65 targeted primarily to GBMSM (3). We report mpox vaccination uptake and course completion among
66 a community sample of GBMSM a year following the 2022 mpox outbreak to complement prior
67 findings on mpox vaccination uptake (1).

68 Using data collected from the 'Reducing inequalities in Sexual Health' (RiiSH) 2023 survey
69 (November-December 2023), part of a series of cross-sectional surveys examining the sexual health
70 and wellbeing of a GBMSM community sample (4), we performed descriptive analyses of vaccination
71 offer and uptake (ever having $\geq 1, 2$ doses) (% , 95% CI), vaccination course completion (2 doses),
72 recency of last dose (June 2022 to survey completion), and method of administration (subcutaneous,
73 intradermal, both) among all participants and those eligible for vaccination. Vaccine eligibility was
74 based on national guidance (5) and defined in the analysis using the following proxy criteria (any of
75 the following since August 2023): ≥ 10 physical male sex partners, meeting a male sex partner(s) in a
76 sex-on-premises venue, sex party, or cruising ground; a positive STI test; and/or in the last year,
77 report of: HIV pre-exposure prophylaxis use; or use of recreational drugs associated with chemsex
78 (crystal methamphetamine, mephedrone or gamma-hydroxybutyrate/gamma-butyrolactone).

79 Of 1,106 participants (median age 44 years [IQR:34-54]; 89% White ethnicity; 78% UK-born; 78%
80 employed; 62% degree-level education; 24% reporting ≥ 10 physical male sex partners in the last 3
81 months), 58% (636/1,106) were eligible for mpox vaccination.

82 Among eligible participants, 66% (419/636) were ever offered an mpox vaccine. Uptake of ≥ 1 mpox
83 vaccine doses was 94% (393/419) among those offered, or 62% (95% CI: 56%-68%, 393/636) in all
84 eligible participants. A minority of eligible participants reported vaccine offer but declined uptake
85 (6%, 26/419). Nearly one-third of eligible participants reported never having received an mpox
86 vaccination offer (29%, 185/636) of which, 65% (121/185) had visited a sexual health service (SHS) in
87 the last year. In those eligible and vaccinated with ≥ 1 dose, 77% (95% CI: 69%-87%, 304/393)
88 reported course completion.

89 In all participants, 46% (508/1,106) were offered an mpox vaccine. Uptake of ≥ 1 mpox vaccine dose
90 was 93% (470/508) among those offered, or 42% (95% CI: 39%-47%, 470/1,106) in all participants.
91 Most participants reporting ≥ 1 mpox vaccine doses met proxy eligibility criteria (84%, 393/470). In
92 participants vaccinated with ≥ 1 dose, 76% (95% CI: 68%-84%, 356/470) reported course completion.
93 Among those with an incomplete vaccination (n=114, only 1 dose), 90% (103/114) were vaccinated
94 before August 2023. In all those vaccinated, most reported exclusive subcutaneous vaccination (68%
95 [77/114] in those with one dose; 50% [179/356] in those with 2 doses).

96 Findings from this community sample indicate vaccination uptake in around two-thirds of
97 participants meeting mpox proxy eligibility criteria with high levels of course completion among all
98 and eligible participants that were ever vaccinated. Vaccine non-offer was a significant barrier to
99 uptake, as nearly a third of those eligible but unvaccinated reported never having received an mpox
100 vaccine offer. Most participants (over 90%) who were ever offered an mpox vaccine reported uptake,
101 but the reasons for not accepting the offer of vaccination were not collected in the survey and may
102 be due to multiple factors such individuals' assessment of their level of risk (6). Given the cross-
103 sectional design of the RiiSH survey, we cannot determine the temporality of vaccination offer in
104 relation to most sexual risk behaviours comprising our vaccination eligibility proxy; however, we
105 found that most participants who did report vaccination met proxy criteria. While RiiSH participants
106 may represent a sample with higher health literacy and social mobility relative to nationally
107 representative GBMSM survey samples (7), our findings represent key populations that are targeted
108 for mpox vaccination where, like similar convenience samples, participants are more likely to report
109 sexual risk behaviours than the general GBMSM population (8).

110 Lessons learned from the 2022 mpox outbreak highlight the importance of a community-supported
111 response and rapid deployment of interventions as part of a series of combination prevention tools.
112 Further studies are needed to understand the individual- and structural-level barriers to mpox
113 vaccination initiation and completion. Continued targeting of vaccination to GBMSM at highest risk
114 of mpox at SHS, with community-support, will help facilitate equitable uptake of vaccination.

115

116 **References**

- 117 1. Ogaz D, Enayat Q, Brown JRG, Phillips D, Wilkie R, Jayes D, et al. Mpox Diagnosis, Behavioral
118 Risk Modification, and Vaccination Uptake among Gay, Bisexual, and Other Men Who Have Sex with
119 Men, United Kingdom, 2022. *Emerg Infect Dis.* 2024;30(5):916-25.
- 120 2. Zhang X-S, Mandal S, Mohammed H, Turner C, Florence I, Walker J, et al. Transmission
121 dynamics and effect of control measures on the 2022 outbreak of mpox among gay, bisexual, and
122 other men who have sex with men in England: a mathematical modelling study. *The Lancet Infectious*
123 *Diseases.* 2024;24(1):65-74.
- 124 3. Department of Health & Social Care. JCVI statement on mpox vaccination as a routine
125 programme, Published 10 November 2023 2023 [cited 2024 03 September]. Available from:
126 [https://www.gov.uk/government/publications/mpox-vaccination-programme-jcvi-advice-10-](https://www.gov.uk/government/publications/mpox-vaccination-programme-jcvi-advice-10-november/jcvi-statement-on-mpox-vaccination-as-a-routine-programme)
127 [november/jcvi-statement-on-mpox-vaccination-as-a-routine-programme](https://www.gov.uk/government/publications/mpox-vaccination-programme-jcvi-advice-10-november/jcvi-statement-on-mpox-vaccination-as-a-routine-programme).
- 128 4. Wayal S, Reid D, Weatherburn P, Blomquist P, Fabiane S, Hughes G, Mercer CH. Association
129 between knowledge, risk behaviours, and testing for sexually transmitted infections among men who
130 have sex with men: findings from a large online survey in the United Kingdom. *HIV Med.*
131 2019;20(8):523-33.
- 132 5. UK Health Security Agency. Smallpox and mpox (monkeypox): the green book, chapter 29
133 2022 [cited 2024 03 September]. Available from:
134 <https://www.gov.uk/government/publications/smallpox-and-vaccinia-the-green-book-chapter-29>.

- 135 6. May T, Towler L, Smith LE, Horwood J, Denford S, Rubin GJ, et al. Mpox knowledge,
136 behaviours and barriers to public health measures among gay, bisexual and other men who have sex
137 with men in the UK: a qualitative study to inform public health guidance and messaging. BMC Public
138 Health. 2023;23(1):2265.
- 139 7. Mercer CH, Prah P, Field N, Tanton C, Macdowall W, Clifton S, et al. The health and well-being
140 of men who have sex with men (MSM) in Britain: Evidence from the third National Survey of Sexual
141 Attitudes and Lifestyles (Natsal-3). BMC Public Health. 2016;16:525.
- 142 8. Prah P, Hickson F, Bonell C, McDaid LM, Johnson AM, Wayal S, et al. Men who have sex with
143 men in Great Britain: comparing methods and estimates from probability and convenience sample
144 surveys. Sex Transm Infect. 2016;92(6):455-63.

145